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Abstract: Improving survival rates in children with malignancy have been achieved at  
the cost of a high frequency of late adverse effects of treatment, especially in intensively 
treated patients such as those undergoing haematopoietic stem cell transplantation (HSCT), 
many of whom suffer the high burden of chronic toxicity. Secondary malignant neoplasms 
(SMNs) are one of the most devastating late effects, cause much morbidity and are the 
most frequent cause of late (yet still premature) treatment-related mortality. They occur in 
up to 7% of HSCT recipients by 20 years post-HSCT, and with no evidence yet of a plateau 
in incidence with longer follow-up. This review describes the epidemiology, pathogenesis, 
clinical features and risk factors of the three main categories of post-HSCT SMNs. A wide 
range of solid SMNs has been described, usually occurring 10 years or more post-HSCT, 
related most often to previous or conditioning radiotherapy. Therapy-related acute myeloid 
leukaemia/myelodysplasia occurs earlier, typically three to seven years post-HSCT, mainly 
in recipients of autologous transplant and is related to previous alkylating agent or 
topoisomerase II inhibitor chemotherapy. Post-transplant lymphoproliferative disorders 
occur early (usually within two years) post-HSCT, usually presenting as Epstein-Barr  
virus-related B cell non-Hodgkin lymphoma. 
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1. Introduction 
The increasing long-term survival rates of children with malignancy, reaching 75%–80% in  
resource-rich countries [1], mean that nearly one in 700 young adults is a survivor of a childhood 
malignancy [2]. However, such impressive survival rates have been accompanied by significant risks 
of late treatment-related toxicity. Overall, 60%–75% of long-term survivors have at least one, and 
30% at least two, chronic medical problems whilst 30%–40% have a severe, life-threatening or 
disabling adverse effect [3–6]. Some groups of survivors, especially those who have undergone more 
intensive treatment with higher doses of chemotherapy or radiotherapy, have even bigger risks of late 
adverse effects (LAEs). Survivors of haematopoietic stem cell transplant (HSCT) represent a 
particularly high risk group. For example, a single-centre cohort study reported an overall cumulative 
incidence of LAEs of 93% in 162 individuals surviving at least two years after paediatric HSCT, 
with 32% suffering from four to six late effects and 24% from a severe burden of LAEs, defined as 
at least seven late effects or at least one severe (CTCAE grade 3) toxicity [7]. The BMT Survivor 
Study, a US two centre cohort study including both paediatric and adult HSCT survivors, reported 
cumulative incidences of 71% for any chronic health condition and 41% for severe or life-threatening 
conditions in 324 10-year survivors [8]. Many treatment-induced late toxicities may have long latent 
periods between the causative treatment and the development of the toxicity. For example, the 
cumulative incidence and the risk of mortality attributable to some life-threatening LAEs such as 
cardiomyopathy and secondary malignant neoplasms (SMNs) continues to rise for several decades 
after completion of treatment, with no evidence so far of a plateau [9,10]. 
Although the nature, severity and outcomes of such LAEs vary widely, some have far-reaching 
consequences. SMNs are one of the most devastating and serious late complications in childhood  
cancer survivors (CCS). They cause considerable morbidity and represent the commonest cause of 
treatment-related late (yet still premature) mortality in individuals who may have been cured of their 
primary malignancy. It is vitally important to understand the nature, risk factors for and causes of 
LAEs in general, but particularly of the more severe ones such as SMNs, in order to develop better 
strategies that will reduce the burden of excess morbidity and mortality faced by CCS without 
compromising the cytotoxic efficacy and success rates of contemporary treatment. Several approaches 
may be used including primary prevention (e.g., health behaviour changes to partially abrogate the 
increased risk of SMNs or vascular disease), surveillance (screening) to permit earlier detection of 
emerging toxicities at a stage when earlier treatment may improve the outcome [11], as well as 
effective treatment of established LAEs (see Armenian 2012 for a description of these approaches in 
anthracycline-induced cardiomyopathy [12]). 
An important proportion of children with higher risk malignancies undergo a HSCT as part of their 
first-line treatment. The proportion differs considerably between specific malignancies and has varied 
greatly across different treatment epochs, depending in part on overall treatment strategies and the 
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perceived benefits and potential risks of transplantation. HSCT in first remission is indicated in 
patients with acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL) who have high 
risk cytogenetic features or high levels of minimal residual disease after induction and/or consolidation 
treatment. Indications in solid tumours include metastatic or poorly responding Ewing sarcoma and 
children presenting with high risk (metastatic or MYCN amplified) neuroblastoma. This final 
indication is the commonest within a specific paediatric malignancy, representing approximately  
half of all children with neuroblastoma [13]. These children have superior survival when intensive, 
multi-modality therapy is consolidated with high dose busulphan/melphalan chemotherapy and 
autologous stem cell rescue [14]. Additionally, HSCT has an important role in the management of 
relapsed/refractory disease, often in heavily pre-treated children, notably those with leukaemia or 
lymphoma. An increasing number of patients from both of these groups become long-term survivors 
and are at very high risk of LAEs for a variety of reasons. These reasons include preceding 
chemotherapy and/or radiotherapy, used either as conditioning for the transplant or during their earlier 
cytotoxic treatment, potentially toxic supportive care drugs, and the consequences of other serious 
complications after HSCT, especially infection and chronic graft-versus-host disease (GvHD). These 
constitute a powerful mix of additive and potentially synergistic chronic toxicities, leading to multiple 
and often severe late effects, most notably SMNs. 
In most cases, SMNs are regarded as occurring secondary to previous treatment, although in some 
cases other genetic and environmental factors may play important roles in their pathogenesis. Indeed, 
some children undergoing HSCT for non-malignant conditions (e.g., bone marrow failure) may 
develop a first malignancy that is secondary to their previous treatment. 
Post-HSCT SMNs fall into three broad categories with important aetiological and clinical 
characteristics (Table 1) [15]. Depending on their underlying disease and their previous treatment, 
some groups of patients may be at particularly high risk of one or more of these categories. Two of 
these categories are clearly related to previous cytotoxic treatment. Secondary, or therapy-related acute 
myeloid leukaemia/myelodysplastic syndrome (t-AML/MDS) tends to occur relatively early (up to 10, 
but classically three to five years) after treatment with chemotherapy (typically alkylating agents or 
topoisomerase II inhibitors), whilst a variety of solid tumours may arise later (usually 10–15 years or more) 
after treatment with radiotherapy. The third category comprises post-transplant lymphoproliferative 
disorders (PTLDs), usually manifesting as an EBV-related B cell non-Hodgkin lymphoma (NHL) 
occurring early post-HSCT (usually within two years). 
In addition, a small number of patients undergo HSCT for life-threatening complications of 
conditions that also confer cancer predisposition. The prototype example is Fanconi anaemia (FA) 
which usually results in bone marrow failure (aplastic anaemia) necessitating HSCT and which is also 
associated with a very high risk of premature malignancy, especially squamous cell carcinoma of the 
head, neck and anogenital mucosal surfaces, in early or middle adulthood [16]. This risk may be 
aggravated further by HSCT or its complications, especially GvHD [17]. 
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Table 1. Features of secondary malignancies following HSCT performed in childhood [13]. Please confirm the highlights. 
Characteristics 
of SMNs 
Related to Previous and/or Conditioning Cytotoxic Treatment 
PTLD 
Solid Tumours t-AML/MDS 
Clinical 
presentation 
Wide variety of sites including skin, 
thyroid, brain, gastrointestinal etc. 
Cytopenias and associated clinical features of bone 
marrow failure, or overt AML with fever, 
lymphadenopathy, coagulopathy etc. 
Spectrum from Glandular fever-like 
illness, lymphadenopathy, lymphomatous 
deposits, fever and organ dysfunction. 
Rarely primary CNS lymphoma 
Incidence 
7% at 20 years post-HSCT, but still 
rising by further 2% for every 
subsequent 5 years additional follow-up 
1%–2% following autologous transplant, but higher with 
intensive pre-transplant chemotherapies. Rarely described 
post allogeneic HSCT 
Approximately 1% overall, up to 70% 
with multiple risk factors 
Latency 
Variable but often long—Up to at least 
20–30 years 
Variable from 6 months for t-AML secondary to 
topoisomerase II inhibitors to 8–10 years for alkylating 
agent induced t-MDS 
Short—Most cases present in first year 
post transplant 
Age at 
presentation 
Any Any Any 
Associated 
features 
Continued rise in cumulative incidence 
even after >20 years post-HSCT 
Topoisomerase II inhibitors associated with an increased 
incidence of rearrangements of, classically, 11q32, but 
also rearrangement of 21q22, t(3;21)(q26.2;q22.1), 
t(15;17)(q22;q12) or inv(16)(p13.1q22). Alkylating agents 
associated with an increased incidence of unbalanced 
cytogenetic changes, especially del(7q) and del(5q) 
EBV viraemia, fever, organ dysfunction 
Risk factors 
Radiotherapy during previous treatment 
or conditioning regimen GvHD 
(especially chronic) 
Epipodophyllotoxin/alkylating agent use PBSC (versus 
marrow) as stem cell source? 
Specific T cell depletion > non-specific 
lymphocyte depletion. Intense 
immunosuppression (after RIC HSCT or 
for treatment of GvHD). Unrelated or 
mismatched related donor 
HSCT—Hematopoietic stem cell transplantation; GvHD—Graft versus host disease; t-therapy related; AML—acute myeloid leukaemia; MDS—Myelodysplasia;  
PBSC—Peripheral blood stem cell; PTLD—Post transplant lymphoproliferative disease; CNS—Central nervous system; EBV—Epstein-Barr virus; RIC—Reduced  
intensity conditioning. 
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2. Epidemiology 
2.1. Secondary Malignant Neoplasms in Childhood Cancer Survivors 
Nearly all the early reports of SMNs in the late 1970s and 1980s were in CCS (rather than survivors 
of adult malignancy), at least in part due to the higher survival rates in this age group which allowed more 
opportunity to develop LAEs in general, including SMNs [18,19]. Although it is now recognised that 
SMNs occur in all age groups, realisation of their true frequency has only emerged in the last 15–20 years. 
Although the relative risk (RR) of developing a SMN (i.e., the increased risk of developing a 
malignancy expressed as a ratio to the risk in a healthy age-matched population) in CCS is relatively 
high, the absolute risk remains low since malignancy is rare per se in childhood. Conversely, even 
though the RR is higher in children than in adults, the absolute frequency of SMNs is higher in the 
adult population because primary malignancies are much commoner in adulthood. Other statistical  
measures employed to quantify SMNs have included the standardised mortality ratio (SMR—an age 
and gender-standardised measure of mortality expressed as a ratio to the mortality rate of the general 
population) and standardised incidence ratio (SIR—a similarly standardised measure of incidence 
expressed as a ratio to the incidence rate in the general population). 
The first large studies in CCS suggested that about 1% of five-year survivors developed a SMN [18,19]. 
Subsequent longer-term single-centre and larger population-based cohort studies from Europe and the 
USA, with post-treatment follow-up extending up to 30 years, reported SMNs in 4%–13% of 
survivors, representing RRs of approximately 4–15 [19–24]. Further studies have revealed the 
implications of these SMNs on long-term mortality. Very long-term data from over 20,000 five-year 
survivors in the North American multi-institutional Childhood Cancer Survivor Study (CCSS) cohort, 
followed up for 16–32 years from initial diagnosis, revealed that they had a SMR of 8.4. Although 57.5% 
of deaths occurring more than five years from initial diagnosis were due to recurrence of the primary 
malignancy itself, most of the remainder resulted from LAEs of treatment, with 18.6% being due to 
second or subsequent malignant neoplasms (SMR 15.2), followed by cardiac (6.9%) and pulmonary 
(2.6%) complications [25]. Moreover, 25 years after diagnosis of childhood malignancy, the death rate 
due to a subsequent malignancy exceeded that due to all other causes combined. This finding was 
confirmed by a separate study of nearly 18,000 five-year survivors in the population-based British 
Childhood Cancer Survivor Study (BCCSS) cohort, in which SMNs accounted for over 50% of the 
excess risk of mortality beyond 45 years from original diagnosis [9]. 
2.2. Secondary Malignant Neoplasms in Survivors of HSCT 
Over the last two decades, several large studies have demonstrated a particularly high risk of SMNs 
in survivors of both adult and childhood HSCT, reporting incidences of up to 10%–15% by 15 years 
post-transplant and highlighting concern that the increased risk of solid SMNs does not plateau even 
after this length of follow-up. Several different patient populations have been studied retrospectively, 
ranging from single institution to multicentre registry cohorts, all HSCT survivors or specifically those 
of allogeneic or autologous transplants or of HSCTs performed for specific indications (e.g., acute 
leukaemia, neuroblastoma), or in specific age groups (e.g., children or adult). Not only have these 
studies addressed different issues relevant to the specific patient and transplant populations, but the 
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contrasting characteristics of these populations have inevitably led to diverse findings regarding the 
epidemiological features of, and risk factors for, post-HSCT secondary malignancies. Table 2 
summarises the characteristics and major results of studies that have described and analysed SMNs 
occurring after HSCT performed in childhood. 
Several large studies, particularly in survivors of adult HSCT, have described the increased risks of solid 
SMNs in general after HSCT [26–36], whilst some have particularly highlighted the risks of oral [37], 
skin (including melanoma, squamous cell carcinoma [SCC] and basal cell carcinoma [BCC]) [28,33,38], 
gastrointestinal [39] and thyroid [40,41] SMNs. A number of studies have highlighted the risk of 
haematological SMNs especially t-AML/MDS [27–30,42], predominantly in survivors of autologous 
HSCT. PTLD, whilst not unique to HSCT survivors, has been well characterised after allogeneic  
HSCTs [27,35,42,43]. 
Several large studies have demonstrated a cumulative risk of solid SMNs of 10%–15% at 15 years 
post-HSCT using Kaplan-Meier analysis, although more recent studies using competing risks analysis 
have shown a lower magnitude of risk of 3%–7%. Early large registry studies used Kaplan-Meier 
analysis to provide important information about the types of SMNs experienced by HSCT survivors.  
A study of five year survivors of autologous or syngeneic (n = 79) or allogeneic (n = 903) HSCT 
survivors transplanted consecutively in 45 European centres before 1986, approximately half of whom 
were transplanted at ≤20 years of age, reported actuarial incidences of all SMNs of 3.5% at 10 years  
and 12.8% at 15 years, with a RR of 3.8 [32]. A study of 3,182 survivors of allogeneic HSCT for 
childhood acute leukaemia performed in 235 centres between 1964 and 1992 also found a high and 
increasing cumulative incidence of SMNs reaching 11% at 15 years, with brain and thyroid tumours 
accounting for 56% of these [35]. In contrast, a more recent very large multicentre international 
registry study of 28,874 patients undergoing allogeneic HSCT between 1964–1996 for leukaemia  
and other severe haematological diseases used competing risks analysis and found a cumulative 
incidence of solid SMNs (excluding PTLD, BCCs and haematological malignancy) of 3.3% at  
20 years post-HSCT [33]. 
Large single centre studies have provided additional data. One study of 2,129 survivors of HSCT 
(64% allogeneic) performed predominantly for haematological malignancies used Kaplan-Meier 
analysis to demonstrate that the incidence of solid SMNs continued to rise to 15% at 15 years  
post-HSCT, with the expectation of additional increases with further follow-up [26]. In contrast, an 
update of the large Minneapolis single centre cohort originally described by Bhatia [27] used 
competing risks analysis and found a cumulative incidence of SMNs of 6.9% at 20 years post-HSCT, 
most of which were solid tumours [42]. However, the incidence continued to rise by about 2% for 
every five years of further follow-up. 
An analysis of 605 adult patients undergoing autologous bone marrow transplantation for NHL  
after conditioning treatment with cyclophosphamide and total body irradiation (TBI) demonstrated 
significant risks both of t-AML/MDS and of solid SMNs. Using competing risks analysis, the overall 
incidence of SMNs (including t-AML/MDS) was 21% by 10 years, split approximately equally 
between t-AML/MDS and other SMNs (including solid tumours and non-MDS haematological 
malignancies) [29]. Again, the incidence of solid tumours continued to rise with longer follow-up 
leading to a projected incidence of all SMNs of 29% by 15 years. 
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Table 2. Secondary malignancies following haematopoietic stem cell transplantation (HSCT) performed in childhood*. 
Author, Date Study Characteristics Secondary Malignancies Risk Factors Comments 
Paediatric Studies 
Socie, 2000 [35] 
Multicentre international registry 
(IBMTR) and Seattle. Allogeneic HSCT 
for acute leukaemia. 3182 patients, 
HSCTs performed 1964–1992.  
Kaplan-Meier analysis of probability of 
SMN. Uni- and multivariate analysis of 
risk factors 
45 invasive SMNs (25 solid 
tumours, 20 PTLDs) compared 
with 1 expected case  
(p < 0.001). Solid tumours 
included brain (9), thyroid (5), 
melanoma (3), tongue SCC (3), 
salivary gland carcinoma (2), 
osteosarcoma (2) 
Solid tumours associated with age <10 years at HSCT 
(RR 3.7) (especially for brain and thyroid SMNs,  
RR 12.2) and high dose TBI (>10 Gy single fraction, 
>13 Gy fractionated) (RR 3.1). NB Chronic GvHD or 
cGvHD lowered risk of solid tumours (RR 0.2). PTLD 
associated with moderate or severe cGvHD (RR 6.5), 
unrelated or HLA mismatched related donor (RR 7.5),  
T cell depletion (RR4.8) and use of ATG (RR 3.1) 
Cumulative incidence of invasive 
solid SMN 0.9%, 4.3% and 11% at 
5, 10 and 15 years post-HSCT 
respectively. Latency—median 6.0 
(range 0.3–14.3) years 
Danner-Koptik, 
2013 [30] 
Multicentre international registry 
(CIBMTR). Autologous HSCT for 
lymphomas or solid tumours. 1487 
patients, HSCTs performed 1987–2003. 
Competing risks (cumulative incidence 
function) analysis of probability of SMN. 
Multivariate analysis of risk factors 
35 SMNs (13 AML/MDS, 20 solid 
tumours). Solid tumours included 
bone (5), thyroid (5), breast (2), 
soft tissue (2). SIRs—overall 24, 
AML 266, MDS 6,603, bone 81, 
thyroid 53, breast 93, soft tissue 34 
No association between risk of SMN and age, gender, 
diagnosis, remission status at HSCT, time from 
diagnosis to HSCT, TBI, etoposide in conditioning, any 
radiotherapy, number of HSCTs, year of HSCT 
Cumulative incidence of SMNs 
1.0% and 2.6% at 5 and 10 years 
post-HSCT (0.6% and 1.1% 
AML/MDS, 0.4% and 1.3% solid 
tumours). Latency—6.3 (0.4–20.4) 
years (AML/MDS—2 years, solid 
tumours—7 years) 
De Latour,  
2014 [44] 
Multicentre international registry 
(EBMT). First HLA-matched allogeneic 
HSCT for Fanconi anaemia. 796 
patients, HSCTs performed 1972–2009 
(49% since 1999). Competing risks 
(cumulative incidence function) analysis 
of probability of SMN. Multivariate 
analysis of risk factors 
30 SMNs (only 2 since 2000).  
89% were solid tumours, including 
20 SCCs (13 were 
oral/oesophageal) 
10–20 or >20 years age at HSCT (HR 2.3 and  
3.3 respectively). Clonal evolution as indication for 
HSCT (HR 4.6). PBSC as stem cell source (HR 3.3). 
Previous cGvHD (HR 3.3). Radiotherapy and donor type 
were not risk factors 
Cumulative risk of SMNs 21% and 
34% at 15 and 20 years post-HSCT 
respectively (in the 509 patients who 
survived >1 year post-HSCT) 
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Table 2. Cont. 
Author, Date Study Characteristics Secondary Malignancies Risk Factors Comments 
Paediatric Studies 
Martin 2014 [45] 
Single centre retrospective analysis of 87 
children undergoing autologous HSCT 
for high risk neuroblastoma. Competing 
risks analysis of probability of SMN. 
Univariate analysis of risk factors 
10 SMNs, including t-AML (1),  
t-MDS (5), papillary thyroid 
carcinomas (2), chondrosarcoma 
followed by hepatocellular 
carcinoma (1), biliary 
adenocarcinoma (1) 
High risk of t-AML/MDS in this study likely to reflect 
the very high dose of cyclophosphamide and etoposide 
compounded by late harvesting of PBSCs 
Cumulative incidence of SMN 7.2%, 
16.5% and 34.2% at 5, 10 and  
15 years respectively 
Bhatia, 1996 [27] 
Single centre USA. Autologous and 
allogeneic HSCT for any diagnosis. 2150 
patients, aged 20.0 (0.2–67) years at 
HSCT performed  
1974–1995. Kaplan-Meier analysis of 
probability of SMN. Uni- and 
multivariate analysis of risk factors 
53 SMNs in 51 patients  
(22 PTLDs, 17 solid tumours,  
11 AML/MDS, 3 lymphoma).  
Solid tumours included melanoma (3), 
BCC (3), brain (2). SIRs—overall 
11.6, solid tumours 3.2, melanoma 
10.3, brain 11.8, AML/MDS 286 
Solid tumours—TBI (RR 6.0) (cGvHD not risk factor 
for skin SMNs). AML/MDS—PBSC as stem cell source 
(RR 5.8), age >35 years at HSCT (RR 3.5). PTLD—in vitro 
T cell depletion (RR 11.9), ATG in conditioning  
(RR 5.9), mismatched donor (RR 8.9), PID (RR 2.5) 
Cumulative risk of SMNs 9.9% at  
13 years post-HSCT. Solid tumours 
5.6% at 13 years. AML/MDS 
plateaued at 2.1% at 9 years, PTLD 
at 1.6% at 4 years. Latency—solid 
tumours 4.0 (0.2–13), AML/MDS 3.0 
(0.3–9) years, PTLD 0.2 (0.1–3) 
Mixed Paediatric/Adult Studies 
Kolb, 1999 [32] 
Multicentre international registry 
(EBMT). Autologous and allogeneic 
HSCT for leukaemia, lymphoma, inborn 
errors or aplastic anaemia. 1,036 patients 
surviving >5 years post-HSCT, aged 21 
(1–51.9) years at HSCT performed 
before 1985. Kaplan-Meier analysis of 
probability of SMN. Uni- and 
multivariate analysis of risk factors 
53 SMNs including skin (14), oral 
(7), gastrointestinal (5), thyroid (5), 
uterine/cervix (5), breast (4),  
brain (3), leukaemia (1) 
Age at HSCT. Immunosuppressive treatment for 
cGvHD, specifically 
• Cyclosporin (RR 2.5) 
• Thalidomide (RR 3.4) 
Cumulative incidence of SMNs 3.5% 
and 11.5% at 10 and 15 years  
post-HSCT respectively 
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Table 2. Cont. 
Author, Date Study Characteristics Secondary Malignancies Risk Factors Comments 
Mixed Paediatric/Adult Studies 
Curtis 1999 [46] 
Multicentre international registry 
(CIBMTR) and Seattle. Allogeneic 
HSCT, excluding patients with primary 
immune deficiency, inherited cancer 
predisposition syndromes, initial 
diagnosis of NHL. 18,014 patients, aged 
25 (<1–72) years at HSCT performed  
1964–1992. Competing risks analysis for 
probability of PTLD. Multivariate 
analysis of risk factors for PTLD 
78 cases of PTLDs with 64 (82%) 
within the first year 
Unrelated or HLA-mismatched related donor  
(RR 4.1). T-cell depletion of donor marrow  
(RR 12.7). Use of antithymocyte globulin (RR 6.4) 
or anti-CD3 monoclonal antibody (RR 43.2). 
Weaker association with grade II-IV aGvHD  
(RR 1.9) and radiation based conditioning (RR 2.9). 
Multiplicative effect of risk factors with 2 major risk 
factors (RR 8.0) and ≥3 factors (RR 22%) 
Cumulative incidence of PTLDs 
1.0% at 10 years post-HSCT. 
Latency—Most PTLDs  
early-onset (64/78 occurred within 
first year post-HSCT), minority late-
onset (14/78 occurred 1–8.6 years 
post-HSCT) 
Bhatia, 2001 [26] 
Single centre USA. Autologous and 
allogeneic HSCT for any diagnosis.  
2129 patients, aged 33.9 (1.5–71.5) years 
at HSCT performed 1976–1998.  
Kaplan-Meier analysis of probability of 
SMN. Uni- and multivariate analysis of 
risk factors. Nested case control study  
of risk factors 
29 solids SMNs. Excluded PTLD and 
haematological malignancies. Included 
non-melanoma skin (9) (SCC 3,  
BCC 6), cervix (4), salivary gland (3), 
oral SCC (3), breast (2), liver (2), 
thyroid (2). Overall SIR (excluding skin 
SCC and BCC) 5.3 if <34 years age at 
HSCT, only 1.1 if older 
Case control study revealed no association between 
risk of SMN and pre-HSCT or conditioning 
radiotherapy or chemotherapy, aGvHD or cGvHD, 
primary diagnosis, age at and type of HSCT 
However 
• All 6 skin SCC patients had cGvHD 
• Both liver cancer patients had history of 
chronic hepatitis C infection 
Cumulative incidence of SMNs 1.6% 
and 6.1% at 5 and 10 years  
post-HSCT respectively (allogeneic 
6.4% and autologous 1.6% at  
10 years). Latency—No data overall, 
but cervix 3.3 (1.6–9.7), oral 7.6 
(4.7–11.7), breast 9.9 (2.6–17.1), 
thyroid 12.7 (7.5–18.0) 
Baker, 2003 [42] 
(NB Update of 
Bhatia 1996) [27] 
Single centre USA. Autologous and 
allogeneic HSCT for any diagnosis. 3372 
patients, aged 24 (0.1–67) years at HSCT 
performed 1974-2001. Competing risks 
analysis of probability of SMN. 
Multivariate analysis of risk factors 
147 invasive SMNs in 137 patients  
(44 PTLDs, 62 solid tumours,  
36 AML/MDS, 5 other 
leukaemia/lymphoma. Solid tumours 
included skin BCC and SCC (19), 
melanoma (8), carcinoma-in-situ (5), 
oral (5), brain (4), breast (4), lung (3). 
SIRs—overall 8.1, solid tumours 2.8, 
AML/MDS 300; if <10 years age at 
HSCT, overall 60.4, solid tumours 33.3 
Solid tumours—Age ≥20 years at HSCT (RR 2.0). 
TBI not significant1. PTLDs—Mismatched related 
donors (RR 9.0), PID (RR 2.7), CML (RR 2.5),  
use of ATG (RR 3.7), in vitro T cell depletion  
(RR 4.0), grade 3–4 aGvHD (RR 2.4). 
AML/MDS—30 of 34 had undergone autologous 
HSCT. Risk highest for PBSC (RR 3.1) 
Cumulative incidence of SMNs 6.9% 
at 20 years post-HSCT, increasing by 
~2% in each successive 5 year 
follow-up period. Mostly solid 
tumours after 5 years (3.8% at  
20 years). Latency—Very similar  
to Bhatia, 1996 
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Table 2. Cont. 
Author, Date Study Characteristics Secondary Malignancies Risk Factors Comments 
Mixed Paediatric/Adult Studies 
Cohen, 2007 [40] 
Multicentre international registry 
(EBMT). Autologous and allogeneic 
HSCT for any diagnosis. 70,859 patients, 
27% aged 0–20 years age at HSCT, 
performed 1985–2003. Competing risks 
analysis of probability of SMN. 
Multivariate analysis of risk factors 
32 thyroid carcinomas (papillary 
cell 23, follicular 9). Presented 
with palpable nodule in 18 (56%). 
No symptoms/signs and diagnosed 
only on ultrasound surveillance in 
9 (28%). SIRs—Overall 3.3,  
males 4.1, females 2.9, 0–10 years 
age at HSCT 61 
Age at HSCT (RR 24.6 for <10 years vs. >20 years). 
TBI or thoraco-abdominal radiotherapy (RR 3.4). 
Females (RR 2.8 vs. males). cGvHD (RR 2.9) 
Cumulative incidence of thyroid 
SMNs ~0.05% at 20 years post-HSCT 
(0.2% in patients 0–10 year age at 
HSCT). Latency—8.5 (0.6–18.5) 
years 
Landgren 2009 [47]. 
(NB Update of 
Curtis 1999) [46] 
Multicentre international registry 
(CIBMTR) and Seattle Allogeneic 
HSCT, excluding patients with primary 
immune deficiency, inherited cancer 
predisposition syndromes, initial 
diagnosis of NHL. 26,901 patients, aged 
26.6 (0.1–68) years at HSCT performed 
1964–1996. Competing risks analysis for 
probability of PTLD. Multivariate 
analysis of risk factors for PTLD 
127 PTLDs identified, 105 (83%) 
within the first year following 
transplant. 
T cell depletion (RR 3.1–9.4), use of ATG (RR 3.8), 
HLA mismatching in presence of T-cell depletion/ATG 
use (RR 3.8), acute (RR1.7) and chronic (RR 2) GvHD. 
Less effect when T-cell depletion used agents which also 
remove B cell 
Overall observed to expected (O/E) 
ratio 29.7 (4.2 at ≥5 years  
post-HSCT). Demonstrated a 
multiplicative effect of multiple 
major risk factors on incidence:  
0 factors—cumulative risk 0.2% at  
12 years post-HSCT; 1 factor—1.1%; 
2 factors—3.6%; 3 factors—8.1%. 
Latency—most PTLDs early-onset 
(105/127 [83%] occurred within first 
year post-HSCT), minority late-onset 
(22/127 occurred 1–>10 years  
post-HSCT) 
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Table 2. Cont. 
Author, Date Study Characteristics Secondary Malignancies Risk Factors Comments 
Mixed Paediatric/Adult Studies 
Rizzo, 2009 [33] 
Multicentre international registry 
(CIBMTR) and Seattle. Allogeneic 
HSCT for haematological malignancy, 
aplastic anaemia (except Fanconi 
anaemia) and haemoglobinopathy.  
28,874 patients, aged 27 (0.08–72.4) years at 
HSCT performed 1964–1996. Competing 
risks analysis of probability of SMN 
(also performed Kaplan-Meier analysis 
for comparison with previous studies). 
Multivariate analysis of risk factors 
189 SMNs. Excluded BCC, PTLD 
and haematological malignancies. 
Included oral/pharyngeal (27), 
melanoma (18), brain (18), thyroid (16), 
breast (13), female genital (9), 
bronchus/lung (8), liver (7),  
soft tissue (7), bone/joint (6). 
SIRs—overall 2.1, bone/joint 8.5, 
oral 7.0, soft tissue 6.5, liver 6.3, 
brain 5.9, thyroid 5.8, melanoma 3.5 
Conditioning radiotherapy (TBI or limited  
field)—non-SCC tumours (RR 2.3 for TBI). Significant 
interaction with age at HSCT – RR 55.3 for <10 years, 
6.2 if 10–19 years, 4.8 if 20-29 years; no excess risk if 
>30 years. cGvHD—SCCs (skin RR 11.0, oral RR 5.3). 
Patient gender (male)—SCCs (skin RR 11.9, oral RR 2.8). 
Most cases (27/40) of brain/CNS, thyroid, bone,  
soft-tissue SMNs occurred in patients who underwent 
HSCT at <17 years age 
Cumulative incidence of solid SMNs 
3.3% (competing risks analysis) and 
8.8% (Kaplan-Meier analysis) at  
20 years post-HSCT.  
Latency—65 SMNs occurred  
1–4 years and 100 ≥5 years  
post-HSCT 
* Studies including at least 500 HSCTs, of which ≥10% performed in children. ATG = anti-thymocyte globulin; BCC = basal cell carcinoma; aGvHD/cGvHD = acute/chronic graft-versus-host disease;  
CIBMTR = Centre for International Blood and Marrow Transplant Research; EBMT = European Society for Blood and Marrow Transplantation; HR = hazard ratio; IBMTR = International Bone Marrow 
Transplant Registry Database; NHL = non-Hodgkin lymphoma; PBSC = peripheral blood stem cells; PID = primary immunodeficiency; RR = relative risk; SCC = squamous cell carcinoma; SIR = standardised 
incidence ratio; TBI = total body irradiation. Patient age at HSCT and latency expressed as median (range). 1 78% of patients had TBI or total lymphoid irradiation, which may therefore have reduced power to 
detect their effect as risk factors. 
 
  
3. Pathogenesis, Clinical Features and Management 
3.1. Solid Malignancies 
A spectrum of solid malignancies is seen following HSCT, with the commonest being skin, oral, 
uterine, thyroid and breast cancer and glioblastoma [32,33]. Whilst their clinical presentation is not 
dissimilar to their de novo counterparts, there is very little information available concerning the 
optimal strategies to treat SMNs in survivors of childhood HSCT. The authors of a single centre 
retrospective analysis suggested that frequent clinical follow-up, based on knowledge of the most 
likely SMNs, may permit more timely diagnosis and hence earlier stage of malignancy at diagnosis, 
thereby offering the possibility of improved outcomes [48]. Appropriate and timely surveillance will 
be an important component of this approach [11]. However, although some studies have demonstrated 
a reasonably good overall outcome in solid SMNs, the reported survival times are short in those who 
do die from their secondary malignancy. For example, both Bhatia’s single centre study and Socie’s 
large multicentre registry study reported that only 40% of patients died from a solid SMN, but stated that 
the SMN-related deaths occurred at a median of 1.5 months in Bhatia’s study, and at between 0.2–2.7 years 
in Socie’s [27,35]. Taken together with the many different types of tumours that have been reported, 
this suggests that there is a wide spectrum in the clinical nature and behaviour of solid SMNs after 
HSCT, probably reflecting different biological mechanisms. 
However, there has been a notable paucity of research into the pathogenetic mechanisms underlying 
solid SMNs in CCS in general, not just in survivors of HSCT, although radiotherapy is believed to  
be the major determinant of risk. For example, Rizzo’s recent very large international multicenter 
registry study was in agreement with previous reports that conditioning radiotherapy, predominantly 
TBI, is an independent risk factor for solid SMNs post-HSCT [27,35,40], and also confirmed that 
secondary breast cancer is one of the commoner solid malignancies in this setting [33]. Radiation is  
a well-documented cause of breast cancer, for example in CCS previously treated with radiotherapy  
to a field including breast tissue [49] and in atomic bomb survivors [50]. Recent work with  
secondary breast cancer is beginning to shed more light on molecular genetic mechanisms that underlie 
radiation-induced malignancy, demonstrating that breast epithelium cell lines and primary cell cultures 
exposed to ionising radiation display particular sensitivity at the c-MYC locus (encoding an oncogenic 
transcription factor), resulting in mutations, notably high level focal amplification, and increased 
protein expression. Furthermore, the frequency and magnitude of c-MYC amplification and protein 
expression were significantly higher in tissue from radiation-related breast cancers compared to that in 
cases unrelated to radiation. The authors concluded that mutation at the c-MYC locus is implicated in 
the pathogenesis of a substantial proportion of radiation-related breast cancer [51]. 
Chronic GvHD (cGvHD), and hence the necessity for often prolonged immunosuppressive 
treatment, is also believed to be an important factor in the development of some solid SMNs, 
particularly mucocutaneous malignancies [32,33]. This appears to be particularly important in patients 
undergoing HSCT for FA [17]. 
Although previous alkylating agent treatment may contribute to the development of bone SMNs in 
CCS in general [52], there is no clear evidence to support the relevance of chemotherapy in the 
development of post-HSCT SMNs. 
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As mentioned above, and in stark contrast to the plateau in incidence seen with t-AML/MDS and 
PTLD, the risk of radiotherapy-associated solid SMNs continues to increase with longer follow-up 
after HSCT, with latency periods of up to 15 years or even longer [33,42]. Clearly, this has important 
implications for surveillance strategies. As the likelihood and duration of survival continues to 
improve after HSCT, it is likely that the full impact of post-HSCT solid SMNs will only be revealed in 
future decades [53]. 
3.2. Myeloid Malignancies—Acute Myeloid Leukaemia and Myelodysplasia 
Therapy-related AML/MDS is predominantly associated with autologous HSCT, occurring mostly 
within the first 10 years after transplant [27,29]. In this setting, the reconstituting haematopoietic stem 
cells (HSCs) have frequently been exposed to cytotoxic chemotherapy prior to harvesting and storage. 
Additionally, many high dose chemotherapy regimens, for example BEAM (carmustine [BCNU] 
etoposide, cytarabine, melphalan) which is frequently used in relapsed paediatric non-Hodgkin 
lymphoma patients, are not truly myeloablative. This allows for the possibility of heavily pre-treated 
and conditioned HSCs undergoing dysplastic and malignant change leading to t-AML/MDS. 
Although the occurrence of t-AML/MDS is thought to reflect the cumulative effects of prior 
chemotherapy/radiotherapy, conditioning and replicative stress, dissecting the respective contributions 
of these factors has proved challenging. The biggest difficulty is the variation in both the previously 
administered therapies, many of which are themselves associated with a risk of t-AML/MDS, and the 
high dose chemotherapy conditioning regimens used for autologous HSCT. Additionally, t-AML/MDS 
has been reported occasionally following allogeneic HSCT [54,55], a clinical situation where the 
reconstituting HSCs should not have experienced pre-transplant toxicity. Several explanations exist for 
this finding—second malignancies may derive from a residual recipient haematopoietic precursor, or 
the pre-treated microenvironment contributes to the development of t-AML/MDS, or there is an impact 
of replicative stress on subsequent malignant change. The latter two possibilities are further supported 
by a relatively high incidence of donor-derived myeloid malignancy post allogeneic HSCT, despite the 
donor remaining well [27,34,42,43]. 
The WHO recognises two subsets of therapy-related myeloid malignancies, those resulting from 
prior use of alkylating agents and those resulting from topoisomerase II inhibitor use [56]. Alkylating 
agents, such as melphalan, chlorambucil, dacarbazine and cyclophosphamide classically result in a 
myelodysplastic syndrome with a peak incidence at five to eight years (range 1–20 years) following 
treatment. Frequently associated with high risk, unbalanced cytogenetic changes, notably del(7q) or 
del(5q), t-MDS has a higher frequency of conversion to AML and does so over a shorter period than 
does spontaneous MDS, with a median time of six months. 
In contrast, second malignancy associated with topoisomerase II inhibitors (etoposide, teniposide, 
anthracyclines) classically presents with a shorter latency of two to three years, usually as t-AML 
without a preceding period of myelodysplasia. This condition is typified by rearrangement of the 
mixed lineage leukaemia (MLL) gene at 11q32, or rearrangement of 21q22, t(3;21)(q26.2;q22.1), 
t(15;17)(q22;q12) or inv(16)(p13.1q22) [56]. 
Current management approaches focus on allogeneic HSCT, with or without prior standard 
chemotherapy, where residual toxicity and suitability of potential donors allows. However, outcome  
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in this group of patients remains poor [27,42]. Bhatia found that eight of 11 patients (73%) with  
t-AML/MDS died [27], whilst an updated report of this large single centre cohort demonstrated a  
one-year survival rate of 34% [42]. 
3.3. Post-Transplantation Lymphoproliferative Disorder 
PTLD represents a spectrum of disease associated with the period of immune suppression following 
either haematopoietic stem cell or solid organ transplantation. In keeping with this, the majority of  
PTLD is associated with viral infection, predominantly Epstein Barr virus (EBV) which is identified in 
55%–80% of patients overall, but approaching 100% of those with early onset PTLD, occurring within 
the first twelve months after transplant [57–59]. Most lesions are of B lineage origin with just 5%–10% 
being NK/T cell or Hodgkin lymphoma. The clinical presentations of PTLD following HSCT are 
varied, ranging from an asymptomatic rise in EBV titre on routine surveillance, to non-specific 
symptoms of fever and malaise, through nodal disease to fulminant and life-threatening PTLD with 
diffuse bulky involvement, fever, hypotension and organ dysfunction. Rarely, a distinct category of 
primary central nervous system PTLD is seen. 
Described by Nalesnik [60], but more recently updated in the WHO Classification of tumours of 
haematopoietic and lymphoid tissues [56], four distinct histopathological entities are recognised. 
Firstly a plasmacytic hyperplasia or infectious mononucleosis-like, or “early lesion”, PTLD. Secondly, 
polymorphic PTLD which shows destruction of normal tissue architecture but retains a broadly 
polymorphic cell population. The occurrence of cytogenetic changes is limited, being seen in only 15% 
of cases [61]. Thirdly, monomorphic PTLD is composed of malignant cells of clonal origin. In this 
group of tumours, cytogenetic abnormalities are seen in up to 70% of cases, including trisomy 9, 
trisomy 11 and rearrangement of 8q24.1 (MYC) [61]. Histological classification is complex. In 
children, the predominant morphology is of diffuse large B cell lymphoma, although Burkitt/Burkitt-like 
lymphoma, Hodgkin lymphoma and plasmacytoid neoplasms are all recognised. Indeed, Hodgkin 
lymphoma/Hodgkin lymphoma-like PTLD is recognised as the fourth WHO category. 
Following allogeneic HSCT, the risk of PTLD is relatively low, being seen in 1%–2% of  
recipients [27,62]. However, in patients receiving T cell depleted transplants the rate of PTLD may be 
as high as 24% [62], although more recent and larger series would suggest a more moderate risk, 
approximately 2% but still with a 3.1–15.8 fold increased risk compared to non-T cell depleted 
transplants [47]. The pattern of occurrence is somewhat different following HSCT as compared with 
solid organ transplant recipients, with onset occurring predominantly within the first year post-transplant, 
with a median time to onset of two months [27,63]. 
Management of PTLD recognises that it is primarily a deficiency of immune surveillance. The 
cornerstone of treatment is therefore reduction of immune suppression (RIS) and this may be sufficient 
to control PTLD, especially in the absence of monomorphic disease [64,65]. In the early onset 
situation post-HSCT, scope for RIS may be limited. Increasingly, therefore, a degree of RIS is 
accompanied by administration of the anti-CD20 monoclonal antibody Rituximab, either in the setting 
of established PTLD [66,67], or pre-emptively in response to rising EBV titres [68,69]. This particular 
approach is well suited to post-HSCT PTLD where the relatively short period of highest risk makes 
intensive monitoring of EBV viral titres feasible. Indications for more intensive treatment, principally 
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cytotoxic chemotherapy, are poorly defined with a lack of prospective treatment trials, especially those 
enrolling patients post-HSCT. Indeed, those trials that do exist frequently exclude post-HSCT patients. 
Patients are more likely to be considered for chemotherapy if they have bulky disease, a monomorphic 
phenotype or failure to respond to RIS or rituximab monotherapy. Outcome amongst this group of 
patients is, however, poor [27,42,63,70,71]. Finally, the use of EBV-specific cytotoxic T lymphocytes 
(CTLs) is increasingly well investigated in small series [72], with the prospect of data from 
randomised trials in the near future. This approach still requires a reduction in immune suppression  
in order to establish effective CTL function and, at present, suffers from the time taken to generate  
EBV-specific cells and the cost of doing so. 
4. Risk Factors 
Several patient, disease and treatment-specific factors may contribute to the risk of a secondary 
malignancy in HSCT survivors. In general terms, patient risk factors include health-related lifestyle 
and behaviour attributes, disease factors include the underlying diagnosis that led to HSCT (e.g., FA as 
a cancer predisposition syndrome) and treatment risk factors include both prior (i.e., months or years 
before HSCT) and conditioning regimen chemotherapy and radiotherapy. Many post-HSCT SMNs 
have multifactorial origins, for example the occurrence of PTLD in EBV-positive patients who are 
heavily immunocompromised either by their underlying disease (especially the severe primary 
immunodeficiencies [PIDs]), conditioning treatment or continued post-HSCT immunosuppressive 
treatment for GvHD, or in many cases a combination of these. Therefore, most studies have employed 
multivariate statistical analyses to account for the multiplicity of potential risk factors for the 
development of post-HSCT SMNs. 
Although a wide variety of SMNs are reported in many different studies, solid tumours typically 
occur in survivors who received TBI during conditioning treatment, or other (e.g., cranial) 
radiotherapy during earlier treatment of their malignancy, whilst haematological SMNs, especially  
t-AML/MDS, are usually seen in survivors of autologous HSCT and have been attributed to extensive 
prior chemotherapy. PTLD usually occurs in recipients of allogeneic HSCT performed for PIDs, 
particularly when using mismatched donors. 
4.1. Solid Malignancies 
The impact of age as a risk factor for the development of post-HSCT SMNs has varied according to 
the study population. In large registry studies of childhood HSCT, younger age (<10 years) at 
allogeneic transplant was associated with greater risk of SMNs, especially brain and thyroid tumours 
(RR 3.7) [35], but age had no effect on the risk after autologous HSCT [30]. Two registry studies 
including both childhood and adult transplants demonstrated higher relative risks in older recipients 
compared to children (RR 2.0) [32,42], but a single centre study with a case control design failed to 
show any effect of age as a risk factor [26]. In contrast Rizzo’s very large multicentre registry 
study found that two thirds of brain, thyroid, bone and soft tissue SMNs occurred in patients aged  
<17 years at HSCT, and that age <10 years at HSCT increased the risk of solid SMN in patients 
receiving TBI [33]. Furthermore, age <10 years has also been shown to be a risk factor for thyroid 
SMNs, with a very high RR of 24.6 compared to age >20 years [40]. 
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Several studies of the effect of conditioning have demonstrated higher risks of SMNs in patients 
who received TBI [27,35], or TBI or thoraco-abdominal radiotherapy [40]. As mentioned above, the 
risk was amplified considerably in younger recipients in Rizzo’s study, with a RR of over 50 in those 
receiving TBI at <10 years [33]. In contrast, no increased risk due to TBI was observed after paediatric 
autologous HSCTs [30], nor in a large combined paediatric/adult single centre study of both 
autologous and allogeneic HSCTs, although the fact that 78% of patients had received TBI or total 
lymphoid irradiation may have limited this study’s power [42]. The single centre cohort/case control 
study mentioned above failed to show any overall effect of TBI on the risk of SMNs, but did find that 
most thyroid, liver and oral cancers occurred in TBI recipients [26]. Previous cranial radiotherapy (i.e., 
given during earlier antileukaemic treatment) may contribute to the later development of brain and 
thyroid SMNs [35]. 
Few studies have specifically investigated the effect of patient gender on post-transplant SMNs. 
Females have a higher risk of thyroid SMNs [26,40], perhaps unsurprisingly given the higher 
prevalence of thyroid cancer in females in the general population. In contrast, higher risks of skin  
and oral/pharyngeal squamous cell carcinomas (SCCs) have been described in males [26,33].  
Danner-Koptik [30] found no influence of gender on the risk after paediatric autologous HSCT. 
The influences of cGvHD and its treatment, particularly on mucocutaneous SMNs, have also been 
investigated with varied findings. Socie’s registry study of paediatric HSCT [35] found that cGvHD 
reduced the risk of solid SMNs (RR 0.2) but two large combined paediatric/adult single centre studies 
found no effect [26,27]. In contrast, two very large multicenter international registry studies have shown 
that cGvHD increased the risk of thyroid (RR 2.9), skin (RR 11.0) and oral (RR 5.3) SMNs [33,40]. 
Furthermore, GvHD is clearly the main risk factor for the development of solid SMNs post-HSCT in 
patients with FA [17]. Immunosuppressive treatment of cGvHD with ciclosporin (RR 2.5) or 
thalidomide (RR 3.4) has been reported to be an independent risk for developing SMNs in a large 
combined (all ages and all HSCT types) registry study [32]. Overall, cGvHD appears to have an 
important role as a risk for mucocutaneous SMNs post-HSCT. 
Unsurprisingly, given its known role in the aetiology of hepatocellular carcinoma in the general 
population, chronic hepatitis C infection has been reported as an additional risk factor for the 
development of post-HSCT liver cancer [26]. 
4.2. Myeloid Malignancies 
Therapy-related AML/MDS is largely, although not exclusively [42], a second neoplasm associated 
with autologous transplantation. This underpins the generally accepted view that the principle 
mechanism of malignant transformation is the genotoxic stress of DNA damaging agents used either  
for prior therapy, stem cell mobilisation or conditioning (which is frequently not myeloablative).  
Pre-existing DNA damage in engrafting stem cells is compounded by a high replicative stress, either 
prior to or following transplantation. In keeping with this, a number of risk factors have been identified 
which relate to exposure to specific cytotoxic chemotherapy agents or replicative burden. However, 
quantifying the relative effects of pre- and peri-transplantation risk factors remains difficult. 
The best defined risk factors for t-AML/MDS are the use of topoisomerase II inhibitors, alkylating 
agents and radiotherapy. Amongst these, etoposide and cyclophosphamide are the most commonly 
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used chemotherapeutic agents in paediatric practice. As described above, each has a characteristic 
presentation and associated cytogenetic abnormalities. Indeed, use of both drugs is associated with 
therapy-related myeloid malignancy and the use of HSCT [55,73]. Beyond the absolute risk associated 
with the use of, particularly, epipodophyllotoxins, there is ongoing debate regarding the relative 
contribution of total dose, with a threshold of 2000 mg/m2 etoposide often cited [74], versus schedule 
of treatment [75]. This has been especially hard to define further, as different doses and schedules are 
commonly compared across disparate trials and in combination with different additional cytotoxic 
drugs. However, one recent report of 87 children undergoing treatment for high risk neuroblastoma 
demonstrated a high incidence of t-AML/MDS, with a 15 year cumulative incidence of 34.2% [45]. 
The authors attribute this to the very intensive use of etoposide and cyclophosphamide in both of the 
regimens studied (CP1—Cyclophosphamide 10 g/m2, etoposide 6400 mg/m2; CP2—Cyclophosphamide 
19.4 g/m2, etoposide 3302 mg/m2) combined with the late harvesting of HSCs. Finally, in children 
treated for relapsed acute lymphoblastic leukaemia, multivariate analysis identified the use of 
etoposide and doses of cyclophosphamide >3000 mg/m2 to be independently associated with the 
risk of developing t-AML/MDS [76]. 
The use of radiation therapy, and particularly total body irradiation (TBI) as part of conditioning 
regimens for autologous transplantation is relatively uncommon in children today. However, some, but 
not all, adult studies have found an increased risk of t-AML/MDS following TBI, especially at higher 
doses [77]. If true, these data provide an interesting perspective, as the effect of TBI must be mediated 
either by residual HSCs surviving conditioning or by changes in the microenvironment. However, a 
recent study found no association between TBI and the risk of t-AML/MDS in children [30]. 
Several studies have identified initial diagnosis of both Hodgkin lymphoma (HL) and non-Hodgkin 
lymphoma (NHL) as risk factors for developing a therapy-related myeloid malignancy. This is in 
accordance with the importance of prior treatment, as lymphoma patients have frequently received 
significant doses of prior chemotherapy and many will undergo autologous transplantation following 
relapse and second line chemotherapy. An Australian BMT registry-based study looked at 7,765 autologous 
transplants in patients over 14 years of age and identified a within cohort SIR of t-AML/MDS of  
26.4 for patients treated for NHL and 35.4 for HL [28]. The combined paediatric/adult single centre 
study by Bhatia identified an increased cumulative probability of t-AML/MDS in lymphoma patients, 
being 13.5% at six years post-transplant, compared to an actuarial risk of t-AML/MDS across the 
whole group of 2.1% at nine years [27]. However, this finding was not identified in the subsequent updated 
study [42] and has not been reproduced in children. Indeed, a large multicentre study of children 
undergoing autologous HSCT did not identify an increased risk in those treated for lymphoma [30]. 
However, in children the indications for autologous transplant differ from those in adults and it is 
noteworthy that each of the three principle indications for autologous transplant in Danner-Koptik’s 
study, namely lymphoma, sarcoma and neuroblastoma, have pre-transplant induction chemotherapy 
backbones containing significant doses of both topoisomerase II inhibitors and alkylating agents. 
The RR associated with each stem cell source is an interesting characteristic which is not fully 
understood. A number of reports have shown an increased risk of t-AML/MDS following autologous 
peripheral blood stem cell (PBSC) transplantation as compared with autologous marrow 
transplantation. Bhatia identified that, within the group of patients receiving autologous transplant for 
lymphoma diagnoses, those receiving PBSC had a significantly higher incidence of t-AML/MDS than 
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those receiving autologous marrow (35.8% versus 4.1% at four years, p = 0.004) [27]. This was 
confirmed by Baker in their follow-up report from the same institution [42] and in a separate cohort of 
467 Hodgkin lymphoma patients (RR 3.1, p = 0.03) [78]. However, not all adult data support this 
finding [28] and the same effect has not been shown in paediatric studies, although this may purely 
reflect the much smaller number of children receiving autologous transplants and the predominant use 
of PBSC in modern high dose regimens. Possible explanations for this finding are that stem cells mobilised 
into the peripheral circulation following chemotherapy are likely not to have completed DNA repair and 
therefore may carry mutations forward into a situation with a high replicative drive, both endogenous 
and exogenous, as growth factors such as G-CSF are frequently used after autologous HSCT. In 
contrast, marrow stem cells are commonly harvested in steady state and therefore less likely to harbour 
mutations. Alternatively, it may be that mobilisation preferentially affects mutated/pre-leukaemic stem 
cells, resulting in a greater proportion of these cells in the harvested product. Either of these 
explanations may hold an equal relevance to paediatric patients and merit further investigation. 
Many of the risk factors discussed above have clear associations with the presumed mechanism of stem 
cell mutation and replicative stress, and the hallmark clinical and genetic features of both topoisomerase II 
inhibitor and/or alkylating agent induced t-AML/MDS seen in children. However, it is noteworthy that 
little evidence exists to demonstrate the role of modifiable risk factors of HSCT itself, as opposed to 
prior chemotherapy, specifically in the paediatric population. The intensive pre-transplant treatment of 
neuroblastoma provides a good example of the importance of differentiating prior treatment from 
transplantation specific factors [45]. Furthermore, the largest multicentre paediatric cohort to report 
autologous transplantation outcomes failed to identify any additional risk attributable to a number of 
established or postulated adult risk factors, including age, gender, diagnosis, use of either TBI or 
etoposide as conditioning or number of autologous transplants [30]. 
4.3. Post-Transplantation Lymphoproliferative Disorder 
The pathogenesis of PTLD is believed to centre on the lack of T cell-mediated suppression of  
EBV-infected B lymphocytes. In the absence of the immune surveillance offered by EBV-specific  
T cells, latently infected B cells (most frequently of donor origin) are able to proliferate unchecked and 
are, therefore, more likely to acquire the additional genetic mutations promoting development  
of polymorphic or monomorphic proliferations. The risk factors for post-HSCT PTLD relate therefore 
to the degree of suppression of EBV-specific T cell numbers and function in comparison with the 
EBV-positive B-cell load. 
In contrast to an overall incidence of PTLD following HSCT of approximately 1%, several studies 
have shown that donor T cell-specific lymphocyte depletion, both in vitro pre- and in vivo post-transplant, 
increases this risk to as much as 24% [62,79]. In a large single centre study of adults and children  
in the US, Bhatia identified a cumulative probability of developing PTLD by 10 years of 11.4% 
following T cell depletion for GvHD prophylaxis and 11.3% following the use of ATG during 
conditioning [27]. The subsequent update of this center’s experience similarly identified a RR of  
4 following T cell depletion and 3.7 following the use of ATG either as part of conditioning or 
treatment for acute GvHD (aGvHD) [42]. Similar RRs were identified in the multicentre paediatric 
report from the IBMTR for both T cell depletion (RR 4.8) and use of ATG (RR 3.1) [35]. A clear 
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difference exists between the greater scale of risk of those methods which selectively deplete T cells or 
T and NK cells only (RR 8.4–15.8) when compared with approaches which unselectively remove 
both B and T lymphocytes, such as Alemtuzumab (RR 3.1–3.2) [47]. 
A factor related to both conditioning approach and graft manipulation is that of donor matching. 
Both single institution and large multicentre registry-based studies have demonstrated a greater RR for 
developing PTLD following unrelated donor and mismatched donor transplants. Bhatia and this 
group’s updated report presented by Baker identified a RR of 8.9 for mismatched transplants and 9.0 
for mismatched related transplants respectively [27,42]. Socie also reported a raised risk from 
unrelated and mis-matched related donors, with a RR of 7.5 [35]. However, the complex interactions 
of donor choice, graft manipulation and GvHD prophylaxis/treatment mean caution is required in 
interpreting the independence and importance of these factors. Amongst nearly 27,000 HSCT 
recipients, an interaction existed between donor selection (unrelated or mismatched related) and T cell 
depletion or ATG use [47]. In this study, recipients of unrelated or greater than 2 HLA-mismatched 
grafts who did not receive T cell depletion or ATG had a RR of PTLD of 0.9. However, the use of an 
unrelated or mismatched (>2 loci) donor significantly enhanced the pre-existing risk from T cell 
depletion, ATG or both by 3.8 fold. 
The impact of GvHD on the risk of developing PTLD is equally complex to define. The larger 
studies already examined have given quite varied estimates of the risk associated with GvHD. In part, 
this may relate to the complex interplay of donor selection, graft manipulation and conditioning, 
discussed in the previous paragraph. These factors are compounded by the subsequent management of 
GvHD which will impose a further burden of immunosuppression on the patient. Whilst Bhatia 
showed a substantial risk from grade IV aGvHD (RR 9.4) [27], the more recent update of this cohort 
identified a rather more modest effect (RR 2.4) with grade III or IV aGvHD [42]. Neither study 
identified any effect from cGvHD. However, Socie failed to identify any risk from aGvHD in 3,182 
children receiving allogeneic HSCT for acute leukaemia, but did identify a RR of 6.5 with moderate or 
severe cGvHD [35]. One study has suggested that cGvHD may be associated with later onset PTLD 
[46], although this may represent a different disease entity to the early onset PTLD most commonly 
seen after HSCT. An update of this large, multi-institutional study identified a small but significant 
impact of both acute and chronic GvHD (RR 1.7 and 2, respectively) [47]. 
In keeping with the hypothesis that PTLD is driven by the lack of EBV-specific T cell immunity in 
the face of EBV-immortalised B cell persistence, the increasing use of non-myeloablative or reduced 
intensity conditioning (RIC) regimens appears to be associated with an increased risk of PTLD [80]. 
Not only does it increase the risk of recipient B cells surviving conditioning, but tolerance of the graft 
is maintained by use of more intensive immunosuppression post-transplant. This results in prolonged 
time to recovery of EBV-specific T cell immunity. In this setting, the use of ATG in the conditioning 
regimen identified a group with an incidence of PTLD of 21%, significantly higher than those 
receiving either myeloablative conditioning (3%) or non-myeloablative conditioning without ATG 
(2%) [81]. These risks are compounded by their use in patients with primary immune deficiency who, 
as mentioned above, have a substantially higher risk of second malignancy following HSCT. 
Furthermore, whilst not identified as a risk factor following myeloablative conditioning, the use of 
cord blood as a stem cell source increases the risk of PTLD following RIC transplants [81]. 
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Whilst a complex interplay clearly exists between multiple factors involved in immunosuppression 
post HSCT, all these factors support the central hypothesis that PTLD is the result of poor EBV-
specific T cell mediated immune reconstitution. Furthermore, the presence of multiple risk factors 
results in a multiplicative effect on an individual’s risk [46,47]. For a specific patient, this allows some 
personalisation of risk of developing PTLD in the setting of, for example, asymptomatic EBV 
viraemia. Further studies may allow for more focused use of pre-emptive immunotherapy (e.g., 
Rituximab) based on the presence or absence of each of the risk factors. 
4.4. Fanconi Anaemia 
FA is associated with an increased risk of primary MDS or AML, usually occurring during the first 
three decades of life, whilst solid tumours are reported increasingly as primary or second malignancies 
during longer follow-up, often but not exclusively in survivors of HSCT. SCCs of the head, neck and 
anogenital regions are the commonest solid tumours reported, but hepatic, brain, renal, skin and breast 
malignancies are also described [16,82–84]. A North American retrospective cohort of 145 FA patients 
described a cumulative incidence of 39% for malignancy (10% leukaemia, 29% solid tumour) by  
48 years of age. Forty-four FA patients had undergone HSCT and the crude rate for solid tumours prior 
to HSCT, AML, or death was 0.7% per year, and 1.99% after HSCT [16]. The rate ratio was 2.79  
(p = 0.07), but the authors commented that the small number of events and person-years in the HSCT 
group limited the utility of this comparison. A German FA Registry study, comprising 181 FA 
patients, reported very similar findings, with a 28% incidence of solid tumours by 49 years of age,  
a higher risk of AML (22% at 36 years age), and a non-significant (p = 0.11) trend to an increased risk 
(hazard ratio 3.8) of solid tumours after HSCT [84]. Although radiotherapy (during HSCT 
conditioning) had previously been regarded as a major risk factor for secondary solid tumours in FA, 
more recent evidence has not demonstrated this [44] and indeed there is clear evidence that the 
occurrence of acute or chronic GvHD is the most important factor [17,85]. 
4.5. Other Cancer Predisposition Syndromes 
Several other extremely rare constitutional bone marrow failure syndromes which are indications 
for HSCT are also regarded as cancer predisposition syndromes. Malignancy, usually solid tumours in 
the third and fourth decades of life, occurs in 10%–15% of dyskeratosis congenita patients, whilst the 
risk of myeloid malignancy (AML/MDS) is increased in Schwachman-Diamond syndrome, congenital 
amegakaryocytic thrombocytopenia and severe congenital neutropenia (Kostmann syndrome). Both 
solid tumours and myeloid malignancy occur in patients with Diamond-Blackfan anaemia. Due to their 
rarity, there is no information about the influence of HSCT on these risks [86]. 
5. Future Research Questions 
With SMNs already known to be a major cause of morbidity and mortality post-HSCT, and with the 
true ongoing longer-term risk of solid SMN as yet not quantified, further studies are required to provide a 
strong evidence base for risk reduction, surveillance and management of SMNs. This must include 
determining more clearly the modifiable risk factors associated with SMNs. Clinical trials will then be 
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required to study the impact of reduced exposure to these factors by, for example, the increased application 
of non-TBI and non-myeloablative conditioning regimens, reduced use of epipodophyllotoxins and/or 
alkylating agents by improved patient stratification, or improved donor matching and hence reduction 
of GvHD. Of course, limiting exposure to the principle risk factor, the need for HSCT, would provide 
the greatest modification in risk. This may be achievable through better patient stratification and delivery 
of appropriate initial treatment intensity, application of molecularly targeted therapies to reduce exposure 
to DNA damaging agents or even replacement of allogeneic donor with alternative, patient-derived stem 
cell technologies. It must be recognised, however, that for many patient groups such as high risk AML 
or neuroblastoma, the greatest threat to successful treatment remains relapse. Efforts to modify the risk 
of developing an SMN must not significantly affect the chance of primary disease control. 
Some risk factors remain, despite our best efforts, but being able to stratify patients based on their 
risk of developing an SMN post-HSCT will allow the focusing of surveillance resources and also 
reduce anxiety for those identified to be at lower risk. As survival increases and with no plateau for the 
risk of solid SMN yet identified, lifelong surveillance is required and so appropriate use of resources will 
become increasingly important. Existing long-term follow-up guidelines differ considerably in the 
nature and frequency of surveillance investigations recommended for survivors of childhood 
malignancy and HSCT, leading to uncertainty about optimum screening practice [11]. Efforts to 
achieve greater consistency and strength of recommendations have been exemplified recently by the 
provision of an evidence base for the required intensity and optimum modality for surveillance for 
secondary breast cancer, permitting a consistent approach across units [49]. 
Finally, many SMNs still have a poorer prognosis than their sporadic counterparts [27,35,42].  
This may result from the prior treatment of patients and resultant existing toxicities, but equally may 
reflect the common occurrence of high risk disease, characterized by recurrent high risk cytogenetic 
features, in this group of patients. Either way, improved risk stratification of SMNs combined with an 
increasing interest in their identification and management is required to improve the survival in these 
patients. One important area for further investigation is the development of a risk-adapted approach to 
pre-emptive treatment of EBV-driven PTLD. Using patient risk features and clinical characteristics, 
better definition can be given to the need for intervention with Rituximab or a similar agent, versus a 
sustained monitoring approach. 
In the longer term, improved understanding of the molecular pathogenesis of post-HSCT SMNs 
may enable safer use of the causative cytotoxic agents and ultimately improved treatment of the SMNs. 
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